Correction: iSpecimen Inc. Announces Pricing of $4 Million Underwritten Offering
iSpecimen Inc . (Nasdaq: ISPC) ('iSpecimen' or the 'Company'), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced on July 24, 2025 the pricing of an underwritten public offering of 5,714,283 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) at a public offering price of $0.70 per share (the 'Offering'). The aggregate gross proceeds to the Company from the Offering are expected to be approximately $4 million, before deducting underwriting discounts and commissions and other estimated offering expenses. The Offering is expected to close on July 25, 2025, subject to the satisfaction of customary closing conditions.
The Company intends to use the net proceeds from the Offering to pay $1,500,000 for marketing and advertising services to be provided by IR Agency LLC, $1,000,000 to fund the initial milestone payment under a definitive agreement with Sales Stack Solutions Corp., and the remainder for working capital and general corporate purposes.
The Offering is being conducted on a firm commitment basis. WestPark Capital, Inc. acted as the Sole Book-Runner in connection with the Offering.
The securities described above are being offered pursuant to a registration statement on Form S-1 (File No. 333-286958), which was declared effective by the Securities and Exchange Commission (the 'SEC') on July 23, 2025. The Offering is being made only by means of a written prospectus that forms a part of the registration statement. A final prospectus relating to the Offering will be filed with the SEC. When available, copies of the final prospectus relating to the Offering may be obtained from WestPark Capital, Inc., 1800 Century Park East, Suite 220, Los Angeles, CA 90077, tel: 310-203-2919, e-mail: [email protected] and will be available on the SEC's website.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About iSpecimen
iSpecimen (Nasdaq: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit www.ispecimen.com .
Safe Harbor Statement
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute 'forward-looking statements.' These statements include, but are not limited to, statements concerning the development of our company. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The reader is cautioned not to rely on such forward-looking statements. Such forward-looking statements relate to future events or our future performance. In evaluating these forward-looking statements, you should consider various factors, including the uncertainty regarding future commercial success; risks and uncertainties associated with market conditions and the Company's ability to satisfy the closing conditions related to the Offering. These and other factors may cause our actual results to differ materially from any forward-looking statements. Forward-looking statements are only predictions and actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the 'Risk Factors' section of the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on April 14, 2025, as well as other SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, iSpecimen specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
[email protected]
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a few seconds ago
- Yahoo
Top Analyst Warn AMD AI Hype May Outpace Reality
Aug 5 - Advanced Micro Devices (NASDAQ:AMD) is riding an 80% rally over the past three months, but Lynx Equity Strategies thinks the stock may be moving too fast for its fundamentals to keep up. Analyst KC Rajkumar raised concerns in a recent note, cautioning that AMD's rise largely rests on high expectations surrounding its MI350/MI355 GPUs and the upcoming MI400X. Warning! GuruFocus has detected 6 Warning Signs with AMD. According to Rajkumar, many investors assume AMD has won key design wins with hyperscalers like Meta Platforms (NASDAQ:META) and Amazon Web Services, but he questions whether AWS has truly adopted AMD's chips. Without AWS, AMD could be leaning too heavily on Meta, he warned. Lynx isn't convinced about the near-term adoption of AMD's GPUs in data centers, despite some analysts forecasting over 30% revenue growth in 2025. The firm also doubts whether AMD's resumed MI308 shipments to China will deliver much upside, considering Beijing's restrictions on chip imports, already affecting Nvidia (NASDAQ:NVDA). Rajkumar sees downside risk, suggesting a $150 price target if consensus EPS for 2026 lands around $6. He believes AMD may have priced in years of growth that haven't materialized yet. This article first appeared on GuruFocus.
Yahoo
a few seconds ago
- Yahoo
PLTR: Wedbush Sees Palantir Hitting $200 as AI Momentum Turns Explosive
Aug 5 - Palantir Technologies (NASDAQ:PLTR) just delivered another standout quarter, beating expectations on both revenue and outlook. The company's surging momentum in AI continues to impress, and analysts are taking notice. Wedbush reiterated its Outperform rating on the stock and lifted its price target from $160 to $200, citing explosive demand for Palantir's AI products. Warning! GuruFocus has detected 7 Warning Signs with WBD. Leading the charge is Palantir's Artificial Intelligence Platform (AIP), which has seen massive traction, especially in the U.S. commercial segment. That division posted 93% year-over-year growth and now accounts for over 30% of total revenue. Notably, U.S. Commercial Total Contract Value surged 222% to $843 million, while overall contract value climbed 141% to $2.79 billion. Wedbush analysts, led by Daniel Ives, believe Palantir is positioned to become a trillion-dollar company as it evolves into the next Oracle (ORCL) of the AI era. With faster deal cycles and expanding enterprise demand, Palantir looks well-prepared to ride the AI revolution long-term. As AI adoption accelerates, Palantir continues gaining enterprise trust with its robust solutions, and Wall Street is clearly bullish on where this momentum leads. This article first appeared on GuruFocus.
Yahoo
a few seconds ago
- Yahoo
MicroStrategy Stock Due for Short-Term Bounce
Software stock MicroStrategy Inc (NASDAQ:MSTR) has been sliding since its July 16, year-to-date peak of $457.22, made worse by a at the beginning of the month. Shares were last seen down 3.6% to trade at $375.23, but could soon stage a short-term bounce. Support lingers below at the $360 level, which captured pullbacks in May and June. Plus, the recent pullback has the equity running into the 80-day moving average, which has preceded bullish activity in the past. Per Schaeffer's Senior Quantitative Analyst Rocky White, MSTR is within 0.75 of the 80-day trendline's 20-day average true range (ATR), after spending at least 80% of the last 10 days and 80% of the last two months above it. Over the past three years, 10 similar signals have occurred, and the equity was higher one month later following seven of them, averaging 16.9% gain. A move of similar magnitude would put the shares at $438.64. Furthermore, short interest currently represents 9.8% of the stock's available float. This leaves plenty for a short squeeze, which could provide tailwinds for MicroStrategy stock. When weighing in, options look like a good way to go. MSTR's Schaeffer's Volatility Index (SVI) of 53% sits in the low 5th percentile of its annual range, meaning options traders are pricing in low volatility expectations. Sign in to access your portfolio
